Efficacy of convalescent plasma in relation to dose of ebola virus antibodies: To the editor

New England Journal of Medicine

Volumn 375, Issue 23, 2016, Pages 2307-2309

  Van Griensven, Johan ^a   Edwards, Tansy ^b   Baize, Sylvain ^c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLAVIRUS ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY TITER; CONTROLLED STUDY; CONVALESCENT PLASMA; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; MAJOR CLINICAL STUDY; PATIENT CODING; PLASMA; PLASMA TRANSFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL; VIRUS LOAD; VIRUS NEUTRALIZATION; BLOOD; IMMUNOLOGY;

ANTIBODIES, VIRAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; PLASMA;

EID: 85002487975     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1609116     Document Type: Letter

References (2)

1. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374: 33-42.
2. Edwards T, Semple MG, De Weggheleire A, et al. Design and analysis considerations in the Ebola-Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak. Clin Trials 2016; 13: 13-21.